Cost savings with clinical solutions: The impact of reforming health and health care economics with integrative therapies

Integrative Cancer Therapies

Volumn 9, Issue 2, 2010, Pages 129-135

  Block, Keith I ^a  

^a Block Center for Integrative Cancer Treatment   (United States)

Author keywords

biopsy; bone marrow transplant; cancer; cost savings; cost effectiveness; exercise; hypnosis; pycnogenol; thromboembolism; vitamin E

Indexed keywords

ALTERNATIVE MEDICINE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; COST CONTROL; COUNSELING; HEALTH CARE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; MORTALITY; NOTE; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE POLICY; INTEGRATED HEALTH CARE SYSTEM; NEOPLASMS; PROCEDURES; UNITED STATES;

COMPLEMENTARY THERAPIES; COST SAVINGS; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE, INTEGRATED; HEALTH CARE COSTS; HEALTH CARE REFORM; HUMANS; NEOPLASMS; UNITED STATES;

EID: 77954187651     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735410373761     Document Type: Note

References (25)

1. Herman PM, Craig BM, Caspi O. Is complementary and alternative medicine (CAM) cost-effective? A systematic review. BMC Complement Altern Med. 2005; 5: 11.
2. Astin JA, Shapiro SL, Eisenberg DM, Forys KL Mind-body medicine: state of the science, implications for practice. J Am Board Fam Pract. 2003; 16: 131-147.
3. Lang EV, Rosen MP Cost analysis of adjunct hypnosis with sedation during outpatient interventional radiologic procedures. Radiology. 2002; 222: 375-382.
4. MacBurney M., Young LS, Ziegler TR, Wilmore DW A cost-evaluation of glutamine-supplemented parenteral nutrition in adult bone marrow transplant patients. J Am Diet Assoc. 1994; 94: 1263-1266.
5. Herman PM, Szczurko O., Cooley K., Mills EJ Cost-effectiveness of naturopathic care for chronic low back pain. Altern Ther Health Med. 2008; 14: 32-39.
6. Fuhr JP Jr, He H., Goldfarb N., Nash DB Use of chromium picolinate and biotin in the management of type 2 diabetes: an economic analysis. Dis Manag. 2005; 8: 265-275.
7. Montgomery GH, Bovbjerg DH, Schnur JB, et al. A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients. J Natl Cancer Inst. 2007; 99: 1304-1312.
8. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun MJ Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
9. Basic report. http://swz.salary.com/salarywizard/layouthtmls/swzl- compresult-national-hc07000207.html. Accessed April 15, 2010.
10. Dimeo F., Bertz H., Finke J., Fetscher S., Mertelsmann R., Keul J. An aerobic exercise program for patients with haematological malignancies after bone marrow transplantation. Bone Marrow Transplant. 1996; 18: 1157-1160
11. Battaglini CL, Hackney AC, Garcia R., Groff D., Evans E., Shea T. The effects of an exercise program in leukemia patients. Integr Cancer Ther. 2009; 8: 130-138.
12. Candrilli S., Mauskopf J. How much does a hospital day cost? http://www.rtihs.org/request/index.cfm?fuseaction=display&PID=6465. Accessed March 12, 2010.
13. Exercise bikes: reviews. http://www.consumersearch.com/exercise-bike- reviews. Accessed March 12, 2010.
14. Belcaro G., Cesarone MR, Genovesi D., et al. Pycnogenol may alleviate adverse effects in oncologic treatment. Panminerva Med. 2008; 50: 227-234.
15. Orlando L., Colleoni M., Nolè F., et al. Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required? Ann Oncol. 2000; 11: 117-118.
16. Weiss RB, Tormey DC, Holland JF, Weinberg VE Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep. 1981; 65: 677-679.
17. Heit JA Cancer and venous thromboembolism: scope of the problem. Cancer Control. 2005; 12 (suppl 1). 5-10.
18. Mandalà M., Barni S., Floriani I., et al. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the "GISCAD-alternating schedule" study findings. Eur J Cancer. 2009; 45: 65-73.
19. Mandalà M., Barni S., Prins M., et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol. 2010; 21: 871-876.
20. Fotopoulou C., duBois A., Karavas AN, et al. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel- containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol. 2008; 26: 2683-2689.
21. Yildiz R., Buyukberber S., Uner A., et al. Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens. Cancer Invest. 2010; 28: 33-37.
22. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm. 2007; 13: 475-486.
23. Khorana AA, Streiff MB, Farge D., et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol. 2009; 27: 4919-4926.
24. Glynn RJ, Ridker PM, Goldhaber SZ, Zee RYL, Buring JE Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. Circulation. 2007 116: 1497-1503.
25. DeVol R., Bedroussian A. An unhealthy America: the economic burden of chronic disease-charting a new course to save lives and increase productivity and economic growth. http://www.milkeninstitute.org/publications/publications. taf?function=detail&ID=38801018&cat=resrep. Accessed May 2, 2010.